Integration of denosumab therapy in the management of giant cell tumors of bone

被引：7
|
作者：
Miles, Daniel T. [1 ]
Voskuil, Ryan T. [2 ,3 ]
Dale, Wood [4 ]
Mayerson, Joel L. [2 ,3 ]
Scharschmidt, Thomas J. [2 ,3 ]
机构：
[1] Univ Tennessee, Coll Med, Dept Orthopaed Surg, Chattanooga, TN USA
[2] Ohio State Univ, James Canc Hosp, Div Musculoskeletal Oncol, Wexner Med Ctr,Nationwide Childrens Hosp, Columbus, OH 43210 USA
[3] Ohio State Univ, Solove Res Inst, Wexner Med Ctr, Nationwide Childrens Hosp, Columbus, OH 43210 USA
[4] Univ Mississippi, Sch Med, Dept Orthopaed & Rehabil, University, MS 38677 USA
来源：
JOURNAL OF ORTHOPAEDICS | 2020年 / 22卷
关键词：
Denosumab; RANKL; Giant cell tumor of the bone (GCTB); PHASE-II TRIAL; LOCAL RECURRENCE; ZOLEDRONIC ACID; BREAST-CANCER; OPEN-LABEL; PROSTATE-CANCER; GENE-EXPRESSION; CATHEPSIN-K; RANK LIGAND; OSTEOPROTEGERIN;
D O I：
10.1016/j.jor.2020.03.020
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.
引用
收藏
页码：38 / 47
页数：10
相关论文
共 50 条
  • [41] Potential biomarkers for monitoring therapy with Denosumab in patients affected by giant cell tumor of bone
    Conti, Amalia
    Luchini, Alessandra
    Castellani, Gastone
    Giampieri, Enrico
    Pazzaglia, Laura
    Pollino, Serena
    Magagnoli, Giovanna
    Palmerini, Emanuela
    Liotta, Lance L.
    Picci, Piero
    Rhoden, Kerry J.
    Benassi, Maria Serena
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
    Sambri, Andrea
    Medellin, Manuel R.
    Errani, Costantino
    Campanacci, Laura
    Fujiwara, Tomohiro
    Donati, Davide Maria
    Parry, Michael
    Grimer, Robert
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2020, 25 (03) : 513 - 519
  • [43] DENOSUMAB FOR RECURRENT METASTATIC GIANT CELL TUMOR OF THE BONE
    Reddy, Kiranmye
    Venkatramani, Rajkumar
    Pagan, Lorimar
    Kukreja, Kamlesh
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [44] Denosumab for giant cell tumour of bone: success and limitations
    Healey, John H.
    LANCET ONCOLOGY, 2019, 20 (12): : 1627 - 1628
  • [45] A recurrent giant cell tumor of bone treated with denosumab
    Stadler, Nicola
    Fingernagel, Thomas
    Hofstaetter, Stefan G.
    Trieb, Klemens
    CLINICS AND PRACTICE, 2015, 5 (01)
  • [46] Giant cell tumor of bone under Denosumab treatment
    Wendling, Daniel
    Guillot, Xavier
    Sondag, Maxime
    Chaigneau, Loic
    Aubry, Sebastien
    Prati, Clement
    JOINT BONE SPINE, 2018, 85 (04) : 491 - 491
  • [47] Giant cell tumour of the bone under treatment with Denosumab
    Gama, J.
    Madeira, J.
    Oliveira, R.
    Faria, C.
    Almeida, V.
    Ramalhosa, F.
    Sepodes, B.
    Fontinha, G.
    Courelas, C.
    Alves, A.
    Cipriano, M. A.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S339 - S339
  • [48] Denosumab for Bone Giant Cell Tumor of the Distal Radius
    Tsukamoto, Shinji
    Mavrogenis, Andreas F.
    Tanzi, Piergiuseppe
    Leone, Giulio
    Ciani, Giovanni
    Righi, Alberto
    Akahane, Manabu
    Honoki, Kanya
    Tanaka, Yasuhito
    Donati, Davide Maria
    Errani, Costantino
    ORTHOPEDICS, 2020, 43 (05) : 284 - +
  • [49] Safety of denosumab in giant-cell tumour of bone
    Thomas, David
    Carriere, Phillipe
    Jacobs, Ira
    LANCET ONCOLOGY, 2010, 11 (09): : 815 - 815
  • [50] Giant-Cell Tumors of the Temporal Bone: Management Strategies
    Isaacson, Brandon
    Berryhill, Wayne
    Arts, H. Alexander
    SKULL BASE-AN INTERDISCIPLINARY APPROACH, 2009, 19 (04): : 291 - 301
12345